Does Praluent Lower LDL?
Yes, Praluent (alirocumab) lowers LDL cholesterol. The PCSK9 inhibitor binds to PCSK9 proteins in the blood, increasing LDL receptor availability on liver cells, which clears more LDL from circulation. Clinical trials showed reductions of 47-61% in LDL levels from baseline at doses of 75-150 mg every two weeks.[1][2]
How Much LDL Reduction Can Patients Expect?
In the ODYSSEY OUTCOMES trial with 18,924 post-heart attack patients, Praluent reduced LDL by a median 31.3 mg/dL (about 36%) compared to placebo, cutting major cardiovascular events by 15%.[1] LDL drops typically start within 4 weeks, peaking at 50-70% in high-risk patients on statins.[2]
Who Gets the Most LDL Benefit?
Patients with high cardiovascular risk—especially those with atherosclerotic disease or familial hypercholesterolemia—see the largest drops, often 60%+ when combined with statins. Monotherapy yields 40-50% reductions. It's FDA-approved for adults needing extra LDL lowering despite max statin doses.[3]
Praluent vs. Repatha: Which Lowers LDL More?
Both PCSK9 inhibitors work similarly, but head-to-head data is limited. Praluent averages 54% LDL reduction; Repatha (evolocumab) hits 59% in similar trials. Choice often depends on insurance, dosing (Praluent every 2-4 weeks; Repatha similar), and side effects like injection-site reactions.[2][4]
What If LDL Doesn't Drop Enough?
Non-responders (under 30% reduction) may have genetic PCSK9 mutations or poor adherence. Doctors switch to Repatha, add ezetimibe, or use inclisiran. Monitoring at 4-8 weeks guides adjustments.[2]
Common Side Effects with LDL Lowering
Injection-site reactions (7%), flu-like symptoms (5%), and rare allergic responses occur. No direct LDL rebound on stopping, but levels rise within weeks. Long-term data shows no excess liver or muscle issues beyond statins.[1][3]
When Does the Patent Expire for Praluent?
Sanofi's key U.S. patents on Praluent expire between 2031-2034, with formulation patents to 2036. Challenges from Amgen and others are ongoing; biosimilars unlikely before 2033.5
[1]: https://www.nejm.org/doi/full/10.1056/NEJMoa1801174
[2]: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-additional-safety-data-praluentalirocumab-reduce-risk-cardiovascular-events
[3]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125559s029lbl.pdf
[4]: https://www.nejm.org/doi/full/10.1056/NEJMoa1612911